As of 2024-07-27, the Relative Valuation of Nektar Therapeutics (NKTR) is (12.88) USD. This relative valuation is based on P/E multiples. With the latest stock price at 1.38 USD, the upside of Nektar Therapeutics based on Relative Valuation is -1033.0%.
The range of the Relative Valuation is (9.67) - (14.09) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 6.2x - 14.7x | 10.2x |
| Forward P/E multiples | 10.1x - 20.5x | 16.7x |
| Fair Price | (9.67) - (14.09) | (12.88) |
| Upside | -800.6% - -1121.1% | -1033.0% |
| Date | P/E |
| 2024-07-26 | -1.44 |
| 2024-07-25 | -1.43 |
| 2024-07-24 | -1.47 |
| 2024-07-23 | -1.55 |
| 2024-07-22 | -1.53 |
| 2024-07-19 | -1.45 |
| 2024-07-18 | -1.41 |
| 2024-07-17 | -1.51 |
| 2024-07-16 | -1.54 |
| 2024-07-15 | -1.46 |
| 2024-07-12 | -1.48 |
| 2024-07-11 | -1.42 |
| 2024-07-10 | -1.39 |
| 2024-07-09 | -1.28 |
| 2024-07-08 | -1.30 |
| 2024-07-05 | -1.35 |
| 2024-07-03 | -1.36 |
| 2024-07-02 | -1.22 |
| 2024-07-01 | -1.27 |
| 2024-06-28 | -1.30 |
| 2024-06-27 | -1.19 |
| 2024-06-26 | -1.13 |
| 2024-06-25 | -1.12 |
| 2024-06-24 | -1.22 |
| 2024-06-21 | -1.21 |
| 2024-06-20 | -1.14 |
| 2024-06-18 | -1.19 |
| 2024-06-17 | -1.22 |
| 2024-06-14 | -1.22 |
| 2024-06-13 | -1.31 |
| 2024-06-12 | -1.35 |
| 2024-06-11 | -1.32 |
| 2024-06-10 | -1.26 |
| 2024-06-07 | -1.32 |
| 2024-06-06 | -1.45 |
| 2024-06-05 | -1.48 |
| 2024-06-04 | -1.46 |
| 2024-06-03 | -1.47 |
| 2024-05-31 | -1.33 |
| 2024-05-30 | -1.32 |
| 2024-05-29 | -1.44 |
| 2024-05-28 | -1.57 |
| 2024-05-24 | -1.71 |
| 2024-05-23 | -1.73 |
| 2024-05-22 | -1.83 |
| 2024-05-21 | -1.78 |
| 2024-05-20 | -1.83 |
| 2024-05-17 | -1.83 |
| 2024-05-16 | -1.88 |
| 2024-05-15 | -1.91 |